載入...
Model-based meta-analysis to evaluate optimal doses of direct oral factor Xa inhibitors in atrial fibrillation patients
The noninferiority of direct oral factor Xa (FXa) inhibitors (rivaroxaban, apixaban, and edoxaban) in treatment of atrial fibrillation were demonstrated compared with warfarin by several large clinical trials; however, subsequent meta-analyses reported a higher risk of major bleeding with rivaroxaba...
Na minha lista:
| 發表在: | Blood Adv |
|---|---|
| Main Authors: | , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
American Society of Hematology
2018
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5965044/ https://ncbi.nlm.nih.gov/pubmed/29760204 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2017013805 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|